ArticleBMC pediatrics2016
Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?
Article in BMC pediatrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Vancomycin in neonatal patients: systematic review and call for standardized dosing and monitoring practices.European journal of clinical pharmacology · 2025Pooled it
- Continuous versus intermittent vancomycin infusions in critically ill children with gram-positive bacterial infections: a randomized controlled trial.BMC infectious diseases · 2026Trial
- State of Vancomycin Dosing in Neonates: An Overview.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Machine-learning prediction of pre-dose pharmacokinetics optimizes initial vancomycin dosing in critically ill children.Frontiers in pharmacology · 2026Article
- Vancomycin Area Under the Curve to Minimum Inhibitory Concentration Ratio for Treatment Effectiveness in Pediatric and Neonatal Staphylococcal Infections: A Systematic Review.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Real-Life Vancomycin Therapeutic Drug Monitoring in Coagulase-Negative Staphylococcal Bacteremia in Neonatal and Pediatric Intensive Care Unit: Are We Underestimating Augmented Renal Clearance?Antibiotics (Basel, Switzerland) · 2023Article
- Comparison of Vancomycin Trough-Based and 24-Hour Area Under the Curve Over Minimum Inhibitory Concentration (AUC/MIC)-Based Therapeutic Drug Monitoring in Pediatric Patients.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Implementation of a Vancomycin Dose-Optimization Protocol in Neonates: Impact on Vancomycin Exposure, Biological Parameters, and Clinical Outcomes.Antimicrobial agents and chemotherapy · 2022Article
- Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?Antimicrobial agents and chemotherapy · 2020Article
- Challenges of Vancomycin Dosing and Therapeutic Monitoring in Neonates.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2020Review
- Impaired Neonatal Immunity and Infection Resistance Following Fetal Growth Restriction in Preterm Pigs.Frontiers in immunology · 2020Article
- Continuous Infusion Vancomycin in Pediatric Patients: A Critical Review of the Evidence.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2020Review
- Maturational changes in vancomycin protein binding affect vancomycin dosing in neonates.British journal of clinical pharmacology · 2019Article
- Continuous-Infusion Vancomycin in Neonates: Assessment of a Dosing Regimen and Therapeutic Proposal.Frontiers in pediatrics · 2019Article
- Factors impacting unbound vancomycin concentrations in neonates and young infants.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Article
- Vancomycin therapeutic drug monitoring and population pharmacokinetic models in special patient subpopulations.Pharmacology research & perspectives · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite differences in types of infection and causative organisms, pharmacokinetic-pharmacodynamic (PKPD) targets of vancomycin therapy derived from adult studies are suggested for neonates. We aimed to identify doses needed for the attainment of AUC/MIC > 400 and AUC/MIC > 300 in neonates with sepsis and correlate these targets with recommended doses and treatment outcome.
methodsNeonates who had Vancomycin therapeutic drug monitoring (TDM) performed between January 1, 2010 and December 31, 2012 were studied. Clinical characteristics, episodes of Gram-positive sepsis with outcomes and all neonatal blood culture isolates in hospital were collected from medical records. To estimate probability of target attainment of AUC/MIC >400 and AUC/MIC >300 a 1000-subject Monte Carlo simulation was performed by calculating AUC using Anderson's (Anderson et al. 2006) and TDM trough concentrations (C
resultsFinal dataset included 76 patients; 57 with confirmed Gram-positive sepsis. TDM was taken after the 1
conclusionWith currently recommended vancomycin dosing the therapeutic target of AUC/MIC > 400 is achieved only by 25% of neonates. Appropriate PKPD targets and respective dosing regimens need to be defined in prospective clinical studies in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.